Clinical trials: Cardiac Diseases
Cardiovascular Disease
Comprehensive Rimonabant Evaluation Study of Cardiovascular ENDpoints and Outcomes
The primary objective is to show whether rimonabant reduces the risk of a heart attack (MI), stroke, or death from an MI or stroke in patients with abdominal obesity with other cardiovascular (CV) risk factors.
- Trial name
- CRESCENDO (NCT00263042)
- Testing
- Rimonabant
- Where
- 43 sites in United States, Argentina and 41 more
- Volunteers
- 18,695 people
- Sponsor
- Sanofi
Atrial Arrhythmia, QT Interval, Variation in
QT Changes as Detected From LINQ ECG During Antiarrhythmic Loading (LINQ QT)
The LINQ QT Study is a prospective, non-randomized, multi-center, observational, post-market clinical study investigating QT interval changes due to antiarrhythmic drug loading.
- Conditions
- Atrial Arrhythmia, QT Interval, Variation in, Arrhythmias, Cardiac
- Trial name
- LINQ QT (NCT05488470)
- Testing
- LINQ/LINQ II
- Where
- 3 sites in United States
- Volunteers
- 22 people
- Sponsor
- Medtronic Cardiac Rhythm and Heart Failure
Hypercholesterolemia
Study of Efficacy, Safety, Tolerability and Quality of Life of Inclisiran (KJX839) vs Placebo, on Top of Ongoing Individually Optimized Lipid-lowering Therapy, in Participants With Hypercholesterolemia
Study of efficacy, safety, tolerability and quality of life of inclisiran (KJX839) vs placebo, on top of ongoing individually optimized lipid-lowering therapy, in participants with hypercholesterolemia
- Trial name
- V-DIFFERENCE (NCT05192941)
- Testing
- Inclisiran Sodium
- Where
- 136 sites in Bulgaria, Czechia and 6 more
- Volunteers
- 1,770 people
- Sponsor
- Novartis Pharmaceuticals
Ventricular Pacing With Rate Response, Bradycardia
Chronic Evaluation of Novel Pacemaker System
The primary study objective is to evaluate the feasibility, initial clinical safety and potential effectiveness of the Calyan Pacemaker system.
- Trial name
- NCT06056817
- Testing
- Calyan Pacemaker
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Calyan Technologies
Atrial Fibrillation, Stroke
CHAMPION-AF Clinical Trial
The primary objective of this study is to determine if left atrial appendage closure (LAAC) with the WATCHMAN FLX device is a reasonable alternative to non-vitamin K oral anticoagulants in patients with non-valvular atrial…
- Conditions
- Atrial Fibrillation, Stroke, Bleeding
- Trial name
- CHAMPION-AF (NCT04394546)
- Testing
- WATCHMAN FLX LAAC Device, Non-Vitamin K Oral Anticoagulant
- Where
- 141 sites in United States, Australia and 14 more
- Volunteers
- 3,000 people
- Sponsor
- Boston Scientific Corporation
Heart Failure
A Comparison Of Outcomes In Patients In New York Heart Association (NYHA) Class II Heart Failure When Treated With Eplerenone Or Placebo In Addition To Standard Heart Failure Medicines
In an earlier study, eplerenone was shown to improve survival in patients who had heart failure immediately following a heart attack.
- Trial name
- EMPHASIS-HF (NCT00232180)
- Testing
- Eplerenone
- Where
- 307 sites in United States, Argentina and 27 more
- Volunteers
- 2,743 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Ischemic Cardiomyopathy, Heart Failure
PET Myocardial Fatty-acid Metabolic Imaging With XTR003 Injection and 18F-FDG to Assess Myocardial Viability in Ischemic Cardiomyopathy
This is a prospective, multicenter, randomized, open-label, parallel-controlled Phase IIb study to investigate the diagnostic-prognostic utility of XTR003 Injection integrated with 18F-FDG as an exploratory clinical trial.
- Trial name
- STB-XTR-003 (NCT07443696)
- Testing
- Fasting XTR003/¹⁸F-FDG PET myocardial metabolic imaging, Glucose-loaded ¹⁸F-FDG PET Myocardial Metabolic Imaging
- Where
- 3 sites in China
- Volunteers
- 40 people
- Sponsor
- Sinotau Pharmaceutical Group
Chronic Stable Angina, Refractory Angina
Wave Crossover ECP Study for Simplified Therapy
The purpose of this study is to demonstrate substantial equivalence between Pression's Wave PRO System and a commercially available predicate ECP device to support a U.S. 510(k) submission for the Wave PRO System.
- Trial name
- WaveCRESST (NCT06571370)
- Testing
- External Counterpulsation
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- Pression
Coronary Artery Disease
Safety and Efficacy Study of PB127 Ultrasound Contrast Agent in Patients With Suspected Coronary Artery Disease 007
This trial is to compare PB127 echocardiography to other heart imaging studies.
- Trial name
- NCT00595673
- Testing
- PB127 for injectable suspension
- Where
- 19 sites in United States
- Volunteers
- 428 people
- Sponsor
- Point Biomedical
Multivessel Coronary Artery Disease
A Multicentre, Pilot Study to Evaluate the Safety and the Feasibility of Planning and Execution of Surgical Revascularization in Patients With Complex Coronary Artery Disease, Based Solely on MSCT Imaging Utilizing GE Healthcare Revolution CT and HeartFlow FFRCT.
The CABG-REVOLUTION study is an investigator-initiated single-arm, multicentre, prospective study for patients with 3-vessel disease (with or without left-main involvement) referred to CABG treatment.
- Trial name
- CABGRevolution (NCT03851276)
- Testing
- Multi-sliced computed tomography (MSCT)
- Where
- 4 sites in Belgium, Germany and 2 more
- Sponsor
- ECRI bv
Heart Failure, Central Sleep Apnea
Central Sleep Apnea Prevalence and Impact on Cognitive Function in Patients With Heart Failure With Reduced or Mildly Reduced Left Ventricular Ejection Fraction
Study to assess the prevalence of central sleep apnea in patients with heart failure with reduced or mildly reduced left ventricular ejection fraction (LVEF <50%) followed by case-control study to assess the link between central…
- Trial name
- COG01 (NCT06313840)
- Where
- Poland
- Volunteers
- 200 people
- Sponsor
- Zoll Medical Corporation
Aortic Valve Disease, Aortic Stenosis
Perceval Sutureless Implant Versus Standard-Aortic Valve Replacement
Prospective, randomized, stratified non blinded multi-center, international, post market trial assessed in a non-inferiority study. The trial has a flexible sample size that will be determined adaptively.
- Trial name
- PERSIST-AVR (NCT02673697)
- Testing
- Perceval valve, other stented biological valve
- Where
- 47 sites in United States, Austria and 10 more
- Volunteers
- 914 people
- Sponsor
- Corcym S.r.l
Heart Failure
AQT90 FLEX NTproBNP2 Test Kit - 23004 - Reference Interval Study
The purpose of this study is to establish the overall (age- and sex independent) at least 95th percentile upper reference limit (URL) of the NTproBNP2 Test Kit on the AQT90 FLEX analyzer.
- Trial name
- RI (NCT06834880)
- Testing
- No intervention; Observational study
- Where
- Finland
- Volunteers
- 781 people, healthy volunteers welcome
- Sponsor
- Radiometer Medical ApS
Atrial Fibrillation
Qatar Cardiovascular Biorepository of AF Patients
Qatar Cardiovascular Biorepsoitory-AF (QCBio-AF) of plasma and DNA of Qatari patients with atrial fibrillation (AF) is to establish.
- Trial name
- NCT03660696
- Where
- Qatar
- Volunteers
- 300 people
- Sponsor
- Hamad Medical Corporation
Persistent Atrial Fibrillation
Persistent Atrial Fibrillation (AF) APAC (Asia Pacific) Observational Study
The objective of this clinical trial is to collect safety and effectiveness data for the TactiCath™ Contact Force Ablation Catheter, Sensor Enabled™ (TactiCath SE) in the APAC patient population for the treatment of drug…
- Trial name
- PerAF APAC (NCT04244396)
- Testing
- TactiCath™ Contact Force Ablation Catheter, Sensor Enabled™ (TactiCath SE)
- Where
- 9 sites in Hong Kong, Singapore and 3 more
- Volunteers
- 82 people
- Sponsor
- Abbott Medical Devices
Heart Block, Valve Heart Disease
Efficacy and Safety of the Sync-AV II Temporary Cardiac Pacing Catheter
This is a prospective, single-center, non-randomized open label study. The objective of this study is to evaluate the efficacy and safety of the Sync-AV II Temporary Cardiac Pacing Catheter in subjects whose elective surgical or…
- Trial name
- NCT06261788
- Testing
- Temporary pacing
- Where
- Paraguay
- Volunteers
- 30 people
- Sponsor
- Swift Sync, Inc.
Peripheral Arterial Diseases
Comparing Angioplasty and DES in the Treatment of Subjects With Ischemic Infrapopliteal Arterial Disease
The primary objective of this study is to compare the performance of the CYPHER SELECTTM + Sirolimus-eluting Balloon-expandable Coronary and Infrapopliteal Stent over balloon angioplasty in de novo and restenotic native below the…
- Trial name
- ACHILLES (NCT00640770)
- Testing
- balloon angioplasty, drug eluting stent
- Where
- Germany
- Volunteers
- 200 people
- Sponsor
- Cordis US Corp.
Heart Failure, Ventricular Dysfunction
Safety and Performance of Electrodes Implanted in the Left Ventricle
The study is intended to demonstrate the safe implant of small receiver-electrodes into the endocardial surface of the left ventricle and to demonstrate its utility in providing cardiac resynchronization therapy in heart failure…
- Conditions
- Heart Failure, Ventricular Dysfunction, Cardiomyopathies, Heart Diseases
- Trial name
- SELECT-LV (NCT01905670)
- Testing
- WiCS-LV system
- Where
- 2 sites in Czechia, Denmark
- Volunteers
- 39 people
- Sponsor
- EBR Systems, Inc.
Ventricular Tachycardia, Coronary Artery Disease
Substrate Modification in Stable Ventricular Tachycardia in Addition to Implantable Cardioverter Defibrillator (ICD) Therapy
The main objective of this study is to compare the time from randomization to the first recurrence of any ventricular tachycardia (VT) in patients undergoing VT ablation (for stable VTs) and substrate ablation (for unstable VTs)…
- Conditions
- Ventricular Tachycardia, Coronary Artery Disease, Left Ventricular Dysfunction
- Trial name
- VTACH (NCT00919373)
- Testing
- Substrate modification, VT ablation, ICD Implantation
- Where
- 16 sites in Czechia, Denmark and 2 more
- Volunteers
- 110 people
- Sponsor
- Abbott Medical Devices
Ischemic Heart Disease
Study to Evaluate the Safety and Effectiveness of the Biosensors Microcatheter in Coronary Chronic Total Occlusions (CTO) - BIOMICS
Biosensors, the Sponsor would like to determine if the Biosensors Microcatheter is safe and effective in treating patients with CTO by assessing a composite of in-hospital cardiac death or myocardial infarction and device success…
- Trial name
- BIOMICS (NCT04966273)
- Testing
- Microcatheter
- Where
- 9 sites in United Kingdom
- Volunteers
- 101 people
- Sponsor
- Biosensors Europe SA
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.